PCYN — what changed in the latest 10-K

Text added vs the prior filing · source: 10-K · 2024-10-25

• We have expanded our product line over the years to address a broader range of wound applications. Our core AMERIGEL product line containing Oakin® established our presence in the physician market to address skin and wound care treatment needs. HELIX3 Bioactive Collagen was added to our product line…

• cancer surgeries, venous diseases and sports injuries. In fiscal 2019, the Company continued expanding its sales channel designed to reduce inventory costs while increasing access to AMERX full line of products, through existing markets. Amerx grew its Wound Care product line with the addition of Re…

• Cybersecurity threats and cybersecurity incidents could adversely affect our business and disrupt our operations. Cybersecurity incidents include an intentional attack or unintentional event allowing unauthorized access to systems impacting the confidentiality, integrity and/or availability of our i…

• To date, Cybersecurity threats have not had a material impact nor, are they anticipated to significantly affect the Company, including our business strategy, results of operations or financial condition.

• We rely extensively on information technology (IT) services to conduct our business. We also rely on networks and services, including internet sites, cloud and software solutions, data hosting and processing facilities and tools and other hardware, software and technical applications and platforms t…

Text removed vs the prior filing · source: 10-K · 2023-09-28

• We have expanded our product line over the years to address a broader range of wound applications. Our core AMERIGEL product line containing Oakin® established our presence in the physician market to address skin and wound care treatment needs. HELIX3 Bioactive Collagen was added to our product line…

• There were no back orders as of June 30, 2023 and June 30, 2022, respectively.

Text added vs the prior filing · source: 10-K · 2024-10-25

• We may be impacted by pandemics or other serious health conditions that could adversely affect our financial conditon and results of operations.

• -Our business may be adversely impacted by disruptions caused by tropical storms.

• The Company has not identified any issues in fiscal year 2024, that could be directly associated with the COVID-19 pandemic.

• During fiscal 2024 and 2023, our results of operations related solely to the operations of AMERX. Net sales during fiscal 2024 were approximately $4,984,000 as compared to approximately $4,687,000 in fiscal 2023, an increase of approximately $297,000 or 6%. The increase in sales was a result of expa…

• Cost of sales were approximately $1,093,000 in fiscal 2024, as compared to approximately $1,117,000 in fiscal 2023, a decrease of approximately $24,000 or 2%. Cost of sales in fiscal 2024, as a percentage of net sales, was 22%, from 24% in the previous fiscal year ending 2023.

Text removed vs the prior filing · source: 10-K · 2023-09-28

• The economic impact of the COVID-19 pandemic could adversely affect our financial condition and results of operations. The pandemic resulted in an unprecedented slow-down in economic activity, a related increase in unemployment and a significant decline in the value of the stock market and many non-…

• The financial effects of COVID-19 started showing their impact on our Company in March of 2020. Due to the timing of these events, the full effect of COVID-19 on our business cannot yet be fully quantified. We have felt the effects of the COVID-19 pandemic in our operations, as management continues …

• The effects were most severely seen in April 2020. This was a direct result of the inability for customers to have elective surgery. Once elective surgeries were permitted again we have seen a steady increase in volume. We continue to monitor operations, and are still implementing procedures to keep…

• During fiscal 2023 and 2022, our results of operations related solely to the operations of AMERX. Net sales during fiscal 2023 were approximately $4,687,000 as compared to approximately $4,842,000 in fiscal 2022, a decrease of approximately $155,000 or 3%. The fluctuation in sales was a result of ex…

• Cost of sales were approximately $1,117,000 in fiscal 2023, as compared to approximately $1,357,000 in fiscal 2022, a decrease of approximately $240,000 or 18%. Cost of sales in fiscal 2023, as a percentage of net sales, was 24%, from 28% in the previous fiscal year ending 2022.